Clinical Utility of Fluid Biomarker in Depressive Disorder

키워드

참고문헌 (62)

1. Depression and other common mental disorders: global health estimates, "World Health Organization", World Health Organization, 21~ (2017)
2. Preece RL, "Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders", Expert Rev Proteomics, 15, pp.325~340 (2018)
3. Roberts MC, "Perspective : the clinical use of polygenic risk scores : race, ethnicity, and health disparities", Ethn Dis, 29, pp.513~516 (2019)
4. Cuthbert BN, "Toward the future of psychiatric diagnosis : the seven pillars of RDoC", BMC Med, 11, pp.126~ (2013)
5. Peng Y, "Failure to identify robust latent variables of positive or negative valence processing across units of analysis", Biol Psychiatry Cogn Neurosci Neuroimaging, 6, pp.518~526 (2021)
6. Ross CA, "Research domain criteria : strengths, weaknesses, and potential alternatives for future psychiatric research", Mol Neuropsychiatry, 5, pp.218~236 (2019)
7. Turck C, "Biomarkers for psychiatric disorders", pp.10~ (2009), Springer New York
8. Ritsner M, "The handbook of neuropsychiatric biomarkers, endophenotypes and genes. Volume III: metabolic and peripheral biomarkers", pp.213~ (2009), Springer Dordrecht
9. Pratt J, "Biomarkers in psychiatry", pp.8~ (2018), Springer Cham
10. Lozupone M, "The role of biomarkers in psychiatry", Adv Exp Med Biol, 1118, pp.135~162 (2019)
11. Gadad BS, "Peripheral biomarkers of major depression and antidepressant treatment response : current knowledge and future outlooks", J Affect Disord, 233, pp.3~14 (2018)
12. Mora C, "Blood biomarkers and treatment response in major depression", Expert Rev Mol Diagn, 18, pp.513~529 (2018)
13. Fabbri C, "Consensus paper of the WFSBP Task Force on Genetics : genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response", World J Biol Psychiatry, 18, pp.5~28 (2017)
14. Şahin OŞ, "Predictors of long-acting injectable antipsychotic prescription at discharge in patients with schizophrenia and other psychotic disorders", Int Clin Psychopharmacol, 36, pp.251~256 (2021)
15. Zhang YY, "Infection is associated with elevated serum concentrations of antipsychotic drugs", Int Clin Psychopharmacol, 36, pp.264~267 (2021)
16. Tatini L, "Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia : relevance of the Drug Attitude Inventory-10", Int Clin Psychopharmacol, 36, pp.181~187 (2021)
17. Khalil AH, "Relation of medication adherence to cognitive functions in Egyptian patients with bipolar I disorder", Int Clin Psychopharmacol, 36, pp.193~200 (2021)
18. Üçok A, "Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder", Int Clin Psychopharmacol, 36, pp.89~96 (2021)
19. Le-Niculescu H, "Precision medicine for mood disorders : objective assessment, risk prediction, pharmacogenomics, and repurposed drugs", Mol Psychiatry, 26, pp.2776~2804 (2021)
20. Bolu A, "Plasma prolidase levels are high in schizophrenia but not in first-episode psychosis", Int Clin Psychopharmacol, 36, pp.25~29 (2021)
21. Green HS, "The dexamethasone suppression test in depression", Clin Neuropharmacol, 6, pp.7~24 (1983)
22. Chiara Fabbri, "How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach", Clinical Psychopharmacology and Neuroscience, 18(4), pp.484~492 (2020), 대한정신약물학회[DOI]
23. Fabbri C, "Genetics and major depressive disorder : clinical implications for disease risk, prognosis and treatment", Int Clin Psychopharmacol, 35, pp.233~242 (2020)
24. Lambert SA, "Towards clinical utility of polygenic risk scores", Hum Mol Genet, 28(R2), pp.R133~R142 (2019)
25. Trubetskoy V, "Mapping genomic loci implicates genes and synaptic biology in schizophrenia", Nature, 604, pp.502~508 (2022)
26. Howard DM, "Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions", Nat Neurosci, 22, pp.343~352 (2019)
27. Fanelli G, "A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response", Eur Neuropsychopharmacol, 55, pp.86~95 (2022)
28. Fanelli G, "Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 108, pp.110170~ (2021)
29. Fanelli G, "Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly", Eur Arch Psychiatry Clin Neurosci, 270, pp.901~910 (2020)
30. Fanelli G, "Reduced CXCL1", GRO chemokine plasma levels are a possible biomarker of elderly depression, 2019, pp.249, 410~417
31. Probst-Schendzielorz K, "CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response : results from the Munich Antidepressant Response Signature(MARS)study", Pharmacogenomics, 16, pp.689~701 (2015)
32. Redei EE, "Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy", Transl Psychiatry, 4, pp.e442~ (2014)
33. Redei EE, "Pilot validation of blood-based biomarkers during pregnancy and postpartum in women with prior or current depression", Transl Psychiatry, 11, pp.68~ (2021)
34. Mamdani F, "Identification of potential blood biomarkers associated with suicide in major depressive disorder", Transl Psychiatry, 12, pp.159~ (2022)
35. Pisanu C, "Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders : a systematic review", Eur Neuropsychopharmacol, 55, pp.112~157 (2022)
36. Göteson A, "A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder", Transl Psychiatry, 12, pp.55~ (2022)
37. Rowland T, "Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder : systematic review and meta-analyses", Br J Psychiatry, 213, pp.514~525 (2018)
38. Rhee SJ, "Comparison of serum protein profiles between major depressive disorder and bipolar disorder", BMC Psychiatry, 20, pp.145~ (2020)
39. Polyakova M, "BDNF as a biomarker for successful treatment of mood disorders : a systematic & quantitative meta-analysis", J Affect Disord, 174, pp.432~440 (2015)
40. Hori H, "Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia", Int Clin Psychopharmacol, 35, pp.89~97 (2020)
41. Haider S, "Integrated analysis of transcriptomic and proteomic data", Curr Genomics, 14, pp.91~110 (2013)
42. Hashimoto K, "Metabolomics of major depressive disorder and bipolar disorder : overview and future perspective", Adv Clin Chem, 84, pp.81~99 (2018)
43. MacDonald K, "Biomarkers for major depressive and bipolar disorders using metabolomics : a systematic review", Am J Med Genet B Neuropsychiatr Genet, 180, pp.122~137 (2019)
44. Benedetti F, "Antidepressant psychopharmacology : is inflammation a future target?", Int Clin Psychopharmacol, 37, pp.79~81 (2022)
45. Chang HH, "Inflammatory biomarkers for mood disorders-a brief narrative review", Curr Pharm Des, 26, pp.236~243 (2020)
46. Elnazer HY, "Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders : exploratory study", Int Clin Psychopharmacol, 36, pp.126~132 (2021)
47. Hannestad J, "The effect of antidepressant medication treatment on serum levels of inflammatory cytokines : a meta-analysis", Neuropsychopharmacology, 36, pp.2452~2459 (2011)
48. Krivoy A, "Low levels of serum vitamin D in clozapine-treated schizophrenia patients are associated with high levels of the proinflammatory cytokine IL-6", Int Clin Psychopharmacol, 35, pp.208~213 (2020)
49. Menetski JP, "The Foundation for the National Institutes of Health Biomarkers Consortium : past accomplishments and new strategic direction", Clin Pharmacol Ther, 105, pp.829~843 (2019)
50. Trujillo J, "A systematic review of the associations between maternal nutritional biomarkers and depression and", or anxiety during pregnancy and postpartum, 2018, pp.232, 185~203
51. Saliha Ozsoy, "Serum Ghrelin and Leptin Levels in Patients with Depression and the Effects of Treatment", PSYCHIATRY INVESTIGATION, 11(2), pp.167~172 (2014), 대한신경정신의학회[DOI]
52. Targum SD, "A novel peripheral biomarker for depression and antidepressant response", Mol Psychiatry, 27, pp.1640~1646 (2022)
53. Cai C, "Is human blood a good surrogate for brain tissue in transcriptional studies?", BMC Genomics, 11, pp.589~ (2010)
54. Tylee DS, "On the outside, looking in:a review and evaluation of the comparability of blood and brain “-omes”", Am J Med Genet B Neuropsychiatr Genet, 162B, pp.595~603 (2013)
55. Kos MZ, "Blood-based miRNA biomarkers as correlates of brain-based miRNA expression", Front Mol Neurosci, 15, pp.817290~ (2022)
56. Lopez JP, "Major depression and its treatment : microRNAs as peripheral biomarkers of diagnosis and treatment response", Curr Opin Psychiatry, 31, pp.7~16 (2018)
57. Zhou L, "Emerging role of microRNAs in major depressive disorder and its implication on diagnosis and therapeutic response", J Affect Disord, 286, pp.80~86 (2021)
58. Liu W, "The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder", Neurosci Lett, 763, pp.136184~ (2021)
59. Rasheed M, "A systematic review of circulatory microRNAs in major depressive disorder : potential biomarkers for disease prognosis", Int J Mol Sci, 23, pp.1294~ (2022)
60. Homorogan C, "Uncovering the roles of microRNAs in major depressive disorder:from candidate diagnostic biomarkers to treatment response indicators", Life(Basel), 11, pp.1073~ (2021)
61. Al Shweiki MR, "Major depressive disorder : insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies", Expert Rev Proteomics, 14, pp.499~514 (2017)
62. Göteson A, "Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder", Mol Psychiatry, 26, pp.7446~7453 (2021)

관련 논문AI추천